Frazier Healthcare Partners

Investor type Private Equity Firm

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 212
Average round size
info
The average size of a deal this fund participated in
$31M
Portfolio companies 126
Rounds per year 6.84
Lead investments 39
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.41
Exits 87
Key employees 17
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

In 1991 was created Frazier Healthcare Partners, which is appeared as VC. The venture was found in North America in United States. The main department of described VC is located in the Seattle.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Frazier Healthcare Partners, startups are often financed by Versant Ventures, Sutter Hill Ventures, Alta Partners. The meaningful sponsors for the fund in investment in the same round are Vivo Capital, Three Arch Partners, Montreux Equity Partners. In the next rounds fund is usually obtained by Versant Ventures, Venrock, Advanced Technology Ventures.

The fund has exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Therapeutics, Medical Device. Among the most popular portfolio startups of the fund, we may highlight AcertaPharma, Zeltiq Aesthetics, Tobira Therapeutics.

The typical startup value when the investment from Frazier Healthcare Partners is 10-50 millions dollars. This Frazier Healthcare Partners works on 4 percentage points more the average amount of lead investments comparing to the other organizations. The fund is constantly included in 7-12 deals per year. The higher amount of exits for fund were in 2015. The high activity for fund was in 2007. Despite it in 2019 the fund had an activity. Deals in the range of 10 - 50 millions dollars are the general things for fund. Considering the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations.

Besides them, we counted 17 critical employees of this fund in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Frazier Healthcare Partners:
Typical Co-investors
Frazier Healthcare Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Frazier Healthcare Partners:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Pardes Biosciences

Biotechnology
Life Science
$75M27 Dec 2021 Carlsbad, California, United States

SanReno Therapeutics

Biotechnology
Therapeutics
$40M30 Nov 2021 Beijing, Beijing, China

Tricida

Health Care
Medical
Pharmaceutical
$42M15 Nov 2021 California, United States

Silence Therapeutics

Biotechnology
Health Care
Information Technology
Medical
Therapeutics
$20M05 Nov 2021 London, England, United Kingdom

Scout Bio

Biotechnology
Health Care
Therapeutics
$33M19 Oct 2021 Philadelphia, Pennsylvania, United States

Radionetics Oncology

Pharmaceutical
Therapeutics
$30M18 Oct 2021 California City, California, United States

Gritstone Oncology

Biotechnology
Health Care
Therapeutics
$55M16 Sep 2021 California, United States

Alpine Immune Sciences

Biotechnology
Health Care
Medical
$91M15 Sep 2021 Seattle, Washington, United States

Crinetics Pharmaceuticals

Biotechnology
Pharmaceutical
Therapeutics
$15M29 Jul 2021 San Diego, California, United States
News
HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate

– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures.
– The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Hummingbird Bioscience Raises US$125M in Series C Financing

– Hummingbird Bioscience from Singapore develops precision therapies against hard-to-drug targets to improve treatment outcomes.
– Series C $125m round brings company valuation to more than $1b.
– The round was led by Novo Holdings with participation from new investors – Frazier Healthcare Partners, Octagon Capital, EDBI, AMGEN Ventures, DROIA Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge Group and Altrium Capital Management and existing investors SK Inc, Heritas Capital, and Mirae Asset Venture Capital.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Frazier Healthcare Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: